Raymond James Financial
SGMT icon

Raymond James Financial’s Sagimet Biosciences SGMT Stock Holding History

Raymond James Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
317,550
+31,300
+11% +$174K ﹤0.01% 3488
2025
Q4 		$1.69M Buy
286,250
+8,004
+3% +$57.5K ﹤0.01% 3398
2025
Q3 		$1.91M Buy
278,246
+13,571
+5% +$110K ﹤0.01% 3207
2025
Q2 		$2.02M Sell
264,675
-81,511
-24% -$344K ﹤0.01% 3079
2025
Q1 		$1.13M Buy
+346,186
New +$1.45M ﹤0.01% 3398

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Raymond James Financial's SGMT Position: Q1 2026 in Review

Raymond James Financial increased its Sagimet Biosciences (SGMT) stake by 11% in Q1 2026, buying an estimated $174K and bringing the position to 317,550 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

Raymond James Financial first reported a position in SGMT in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.02M in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Raymond James Financial held 317,550 shares of Sagimet Biosciences worth $1.66M as of Q1 2026.
  • Raymond James Financial bought 31,300 Sagimet Biosciences shares in Q1 2026, an estimated $174K.
  • Sagimet Biosciences made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3488 holding.
  • Raymond James Financial first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Raymond James Financial's Sagimet Biosciences position peaked at $2.02M in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.